Biotech · Private company
Proteon Therapeutics
Track this companyFree. Adds Proteon Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- PRT-201Phase 3 · Chronic Kidney DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- VonapanitasePhase 3 · Chronic Kidney DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- vonapanitasePhase 1 · Peripheral Artery DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)PHASE1 · COMPLETED · started Nov 1, 2016ClinicalTrials.gov NCT02956993 · fetched Nov 12, 2026
- A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)PHASE3 · COMPLETED · started Aug 1, 2015ClinicalTrials.gov NCT02414841 · fetched Nov 12, 2026
- A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)PHASE3 · COMPLETED · started Jul 1, 2014ClinicalTrials.gov NCT02110901 · fetched Nov 12, 2026
- Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal ArteriesPHASE1 · WITHDRAWNClinicalTrials.gov NCT02953496 · fetched Nov 12, 2026